gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1438Research ArticleГЕПАТОЛОГИЯHEPATOLOGYВозможности противовирусной терапии у больных циррозом печени в исходе HCV-инфекцииPotentials of antiviral therapy at patients with liver cirrhosis in an outcome of HCV-infectionБессоноваЕ. Н.BessonovaE. N.Государственное учреждение здравоохранения «Свердловская областная клиническая больница № 1»Россия2011060620112144351Copyright © Бессонова Е.Н., 20112011Бессонова Е.Н.Bessonova E.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1438

Цель исследования. Изучение эффективности и осложнений противовирусной терапии у больных циррозом печени HCV-этиологии.Материал и методы. В исследование было включено 57 больных циррозом HCV-этиологии классов А и В по шкале Child–Pugh, лечившихся в Свердловском областном гепатологическом центре на базе ГУЗ «Свердловская областная клиническая больница № 1» (г. Екатеринбург) в период 2008–2010 гг. Обследуемые были разделены на две группы: первая (27 человек) получала противовирусную терапию (ПВТ), вторая (30 человек) – не получала.Результаты. Наиболее значимым фактором положительного ответа на ПВТ (даже временного) является не 1-й генотип вируса С. Различия в средних показателях MELD в исследуемых группах пациентов на момент начала наблюдения и после его окончания показывают, что проведение ПВТ позволяло сохранить степень тяжести цирроза на прежнем уровне без дальнейшего прогрессирования, а в некоторых случаях при достижении положительного ответа на противовирусное лечение достичь определенного регресса заболевания.Выводы. Оптимальными кандидатами для проведения противовирусной терапии являются больные более молодого возраста с HCV-ассоциированным циррозом печени класса А по шкале Child– Pugh, с не 1-м генотипом. При назначении данного лечения следует учитывать высокий риск развития инфекционных осложнений.

Aim of investigation

Aim of investigation. To study efficacy and complications of antiviral therapy in patients with liver cirrhosis of HCV-etiology.

Material and methods

Material and methods. Original study included 57 patients with liver cirrhosis of HCV-etiology of A and B classes by Child-Pugh, treated in Sverdlovsk regional center of hepatology, based on «Sverdlovsk regional hospital №1» (Yekaterinburg) in 2008 to 2010. All patients were separated into two groups: the first (27 cases) received antiviral therapy (AVT), the second (30 cases) – received no AVT.

Results

Results. The most significant factor of the positive response to AVT (even transient) was presence of non-1-st genotype of the virus C. Differences in average MELD indices in studied groups of patients at the moment of the investigation onset and after its termination show, that AVT allowed to maintain the degree of severity of cirrhosis at initial level without further progression, and in some cases at achievement of the positive response to antiviral treatment, to reach certain regression of disease.

Conclusions

Conclusions. Optimal candidates for antiviral therapy are patients of younger age with the HCV-associated liver cirrhosis of Child-Pugh A and B classes, with non 1-st genotype. At prescription of this treatment it is necessary to take into account high risk of infections development.

цирроз печенипротивовирусная терапиягенотип вирусаliver cirrhosisantiviral therapyvirus genotypeReferencesBerenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin // J. Hepatol. – 2008. – N 49. – P. 274–287.Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin // J. Hepatol. – 2008. – N 49. – P. 274–287.Berenguer M., Ferrell L., Watson J. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years // J. Hepatol. – 2000. – Vol. 32, N 4. – P. 673–684.Berenguer M., Ferrell L., Watson J. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years // J. Hepatol. – 2000. – Vol. 32, N 4. – P. 673–684.Bzowej N., Nelson D., Thommes J. et al. Randomized controlled trial of prophylactically administered peginterferon alfa-2a plus ribavirin vs no prophylaxis following orthotopic liver transplantation for hepatitis C: a report of initial safety and tolerability [abstract] // Hepatology. – 2006. – Vol.44 (suppl 1). – P. 188Bzowej N., Nelson D., Thommes J. et al. Randomized controlled trial of prophylactically administered peginterferon alfa-2a plus ribavirin vs no prophylaxis following orthotopic liver transplantation for hepatitis C: a report of initial safety and tolerability [abstract] // Hepatology. – 2006. – Vol.44 (suppl 1). – P. 188Сharlton M., Ruppert K., Belle S.H. et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database // Liver Transplant. – 2004. – Vol. 10, N 9. – P. 1120–1130.Сharlton M., Ruppert K., Belle S.H. et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database // Liver Transplant. – 2004. – Vol. 10, N 9. – P. 1120–1130.Crippin J.S., McCashland T., Terrault N. et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation // Liver Transplant. – 2002. – Vol. 8, N 4.– P. 350–355.Crippin J.S., McCashland T., Terrault N. et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation // Liver Transplant. – 2002. – Vol. 8, N 4.– P. 350–355.Everson G.Т. Treatment of patients with hepatitis C virus on the waiting list // J. Hepatol. – 2005. – Vol. 42, N 4. – P. 456–462.Everson G.Т. Treatment of patients with hepatitis C virus on the waiting list // J. Hepatol. – 2005. – Vol. 42, N 4. – P. 456–462.Everson G.T., Trotter J., Forman L. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy // Неpatology. – 2005. – Vol. 42. – P. 255–262.Everson G.T., Trotter J., Forman L. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy // Неpatology. – 2005. – Vol. 42. – P. 255–262.Forman L.M., Lewis J.D., Berlin J.A. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation // Gastroenterology. – 2002. – Vol. 122, N 4. – P. 889–896.Forman L.M., Lewis J.D., Berlin J.A. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation // Gastroenterology. – 2002. – Vol. 122, N 4. – P. 889–896.Forns X., Navasa M., Rodes J. Treatment of HCV infection in patients with advanced cirrhosis // Hepatology. – 2004. – Vol. 40, N 2. – P. 498–501.Forns X., Navasa M., Rodes J. Treatment of HCV infection in patients with advanced cirrhosis // Hepatology. – 2004. – Vol. 40, N 2. – P. 498–501.Gane E.J., Naoumov N.V., Qian K.P. et al. Longitudinal analysis of hepatitis C virus replication following liver transplantation // Gastroenterology. – 1996. – Vol. 110, N 1. – P. 167–177.Gane E.J., Naoumov N.V., Qian K.P. et al. Longitudinal analysis of hepatitis C virus replication following liver transplantation // Gastroenterology. – 1996. – Vol. 110, N 1. – P. 167–177.Gane E.J., Portmann B.C., Naoumov N.V. et al. Longterm outcome of hepatitis C virus infection after liver transplantation // N. Engl. J. Med. – 1996. – Vol. 334, N 13. – P. 815–820.Gane E.J., Portmann B.C., Naoumov N.V. et al. Longterm outcome of hepatitis C virus infection after liver transplantation // N. Engl. J. Med. – 1996. – Vol. 334, N 13. – P. 815–820.Guerrero R.B., Batts K.P., Burgart L.J. et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study // Modern Pathology. – 2000. – Vol. 13, N 3. – P. 229–237.Guerrero R.B., Batts K.P., Burgart L.J. et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study // Modern Pathology. – 2000. – Vol. 13, N 3. – P. 229–237.Iacobellis A., Siciliano M., Perri F. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis:a controlled study // J. Hepatol. – 2007. – N 46. – P. 206–212.Iacobellis A., Siciliano M., Perri F. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis:a controlled study // J. Hepatol. – 2007. – N 46. – P. 206–212.Norah A., Terrault Н. Hepatitis C Therapy Before and After Liver Transplantation. Division of Gastroenterology, Department of Medicine, University of California–San Francisco, San Francisco, CA // Liver Transplant. – 2008. – N 14. – P. 58–66.Norah A., Terrault Н. Hepatitis C Therapy Before and After Liver Transplantation. Division of Gastroenterology, Department of Medicine, University of California–San Francisco, San Francisco, CA // Liver Transplant. – 2008. – N 14. – P. 58–66.Sangionvanni A., Prati G.M., Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients // Hepatology. – 2006. – Vol. 43. – P. 1303–1310.Sangionvanni A., Prati G.M., Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients // Hepatology. – 2006. – Vol. 43. – P. 1303–1310.Sreekumar R., Gonzalez-Koch A., Maor-Kendler Y. et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation // Hepatology. – 2000. – Vol. 32, N 5. – P. 1125–1130.Sreekumar R., Gonzalez-Koch A., Maor-Kendler Y. et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation // Hepatology. – 2000. – Vol. 32, N 5. – P. 1125–1130.Tekin F., Gunsar F., Karasu Z. et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics // Aliment. Pharmacol. Ther. – 2008. – N 27. – P. 1081–1085.Tekin F., Gunsar F., Karasu Z. et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics // Aliment. Pharmacol. Ther. – 2008. – N 27. – P. 1081–1085.

The authors declare that there are no conflicts of interest present.